# Aveanna Healthcare Holdings, Inc.: financial statements, quarterly

AVAH · Nasdaq · CIK 1832332 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jan 1

Pages: [Overview](/companies/avah.md) · [Financials](/companies/avah/financials.md) · [Filings](/companies/avah/filings.md) · [Insiders](/companies/avah/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/avah/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-30) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q4 FY2024 (2024-12-28) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q4 FY2025 (2026-01-03) | Q1 FY2026 (2026-04-04) | Q2 FY2026 (2026-07-04) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [478](/filings/0000950170-24-122748.md) | [479 d](/filings/0000950170-25-038504.md) | [491](/filings/0000950170-25-066342.md) | [505](/filings/0000950170-25-104528.md) | [509](/filings/0001193125-25-267978.md) | [520 d](/filings/0001193125-26-115851.md) | [559](/filings/0001193125-26-222736.md) | [590](/filings/0001193125-26-347842.md) | [622](/filings/0001193125-25-267978.md) | [662 d](/filings/0001193125-26-115851.md) | [648](/filings/0001193125-26-222736.md) | [670](/filings/0001193125-26-347842.md) |
| Gross profit | $m | [147](/filings/0000950170-24-122748.md) | [148 d](/filings/0000950170-25-038504.md) | [146](/filings/0000950170-25-066342.md) | [158](/filings/0000950170-25-104528.md) | [160](/filings/0001193125-25-267978.md) | [172 d](/filings/0001193125-26-115851.md) | [184](/filings/0001193125-26-222736.md) | [211](/filings/0001193125-26-347842.md) | [203](/filings/0001193125-25-267978.md) | [213 d](/filings/0001193125-26-115851.md) | [205](/filings/0001193125-26-222736.md) | [219](/filings/0001193125-26-347842.md) |
| Selling, general and administrative | $m | [91.0](/filings/0000950170-24-122748.md) | [87.0 d](/filings/0000950170-25-038504.md) | [87.9](/filings/0000950170-25-066342.md) | [88.0](/filings/0000950170-25-104528.md) | [88.2](/filings/0001193125-25-267978.md) | [88.7 d](/filings/0001193125-26-115851.md) | [91.4](/filings/0001193125-26-222736.md) | [90.1](/filings/0001193125-26-347842.md) | [95.4](/filings/0001193125-25-267978.md) | [97.6 d](/filings/0001193125-26-115851.md) | [95.8](/filings/0001193125-26-222736.md) | [97.1](/filings/0001193125-26-347842.md) |
| Operating income | $m | [(76.4)](/filings/0000950170-24-122748.md) | [29.3 d](/filings/0000950170-25-038504.md) | [22.9](/filings/0000950170-25-066342.md) | [37.1](/filings/0000950170-25-104528.md) | [34.0](/filings/0001193125-25-267978.md) | [45.8 d](/filings/0001193125-26-115851.md) | [51.8](/filings/0001193125-26-222736.md) | [80.0](/filings/0001193125-26-347842.md) | [53.6](/filings/0001193125-25-267978.md) | [71.0 d](/filings/0001193125-26-115851.md) | [69.3](/filings/0001193125-26-222736.md) | [80.0](/filings/0001193125-26-347842.md) |
| Interest expense | $m | [39.6](/filings/0000950170-24-122748.md) | [39.7 d](/filings/0000950170-25-038504.md) | [39.6](/filings/0000950170-25-066342.md) | [39.6](/filings/0000950170-25-104528.md) | [39.2](/filings/0001193125-25-267978.md) | [38.1 d](/filings/0001193125-26-115851.md) | [36.3](/filings/0001193125-26-222736.md) | [36.0](/filings/0001193125-26-347842.md) | [35.1](/filings/0001193125-25-267978.md) | [32.6 d](/filings/0001193125-26-115851.md) | [29.2](/filings/0001193125-26-222736.md) | [27.8](/filings/0001193125-26-347842.md) |
| Income tax | $m | [0.6](/filings/0000950170-24-122748.md) | [(5.9) d](/filings/0000950170-25-038504.md) | [12.7](/filings/0000950170-25-066342.md) | [(9.9)](/filings/0000950170-25-104528.md) | [15.5](/filings/0001193125-25-267978.md) | [(2.2) d](/filings/0001193125-26-115851.md) | [5.0](/filings/0001193125-26-222736.md) | [17.1](/filings/0001193125-26-347842.md) | [(0.6)](/filings/0001193125-25-267978.md) | [(140) d](/filings/0001193125-26-115851.md) | [3.3](/filings/0001193125-26-222736.md) | [16.2](/filings/0001193125-26-347842.md) |
| Net income | $m | [(102)](/filings/0000950170-24-122748.md) | [(25.7) d](/filings/0000950170-25-038504.md) | [(11.2)](/filings/0000950170-25-066342.md) | [13.9](/filings/0000950170-25-104528.md) | [(42.8)](/filings/0001193125-25-267978.md) | [29.2 d](/filings/0001193125-26-115851.md) | [5.2](/filings/0001193125-26-222736.md) | [27.0](/filings/0001193125-26-347842.md) | [14.1](/filings/0001193125-25-267978.md) | [179 d](/filings/0001193125-26-115851.md) | [41.7](/filings/0001193125-26-222736.md) | [40.3](/filings/0001193125-26-347842.md) |
| Diluted EPS | $ per share | [(0.54)](/filings/0000950170-24-122748.md) | not reported | [(0.06)](/filings/0000950170-25-066342.md) | [0.07](/filings/0000950170-25-104528.md) | [(0.22)](/filings/0001193125-25-267978.md) | not reported | [0.03](/filings/0001193125-26-222736.md) | [0.13](/filings/0001193125-26-347842.md) | [0.06](/filings/0001193125-25-267978.md) | not reported | [0.19](/filings/0001193125-26-222736.md) | [0.18](/filings/0001193125-26-347842.md) |
| Basic EPS | $ per share | [(0.54)](/filings/0000950170-24-122748.md) | not reported | [(0.06)](/filings/0000950170-25-066342.md) | [0.07](/filings/0000950170-25-104528.md) | [(0.22)](/filings/0001193125-25-267978.md) | not reported | [0.03](/filings/0001193125-26-222736.md) | [0.13](/filings/0001193125-26-347842.md) | [0.07](/filings/0001193125-25-267978.md) | not reported | [0.19](/filings/0001193125-26-222736.md) | [0.19](/filings/0001193125-26-347842.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Gross profit: us-gaap:GrossProfit
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-30) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | FY2024 (2024-12-28) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | FY2025 (2026-01-03) | Q1 FY2026 (2026-04-04) | Q2 FY2026 (2026-07-04) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [48.3](/filings/0000950170-23-061484.md) | [43.9](/filings/0000950170-25-038504.md) | [42.6](/filings/0000950170-24-056215.md) | [47.7](/filings/0000950170-24-093268.md) | [78.5](/filings/0000950170-24-122748.md) | [84.3](/filings/0001193125-26-115851.md) | [71.5](/filings/0000950170-25-066342.md) | [101](/filings/0000950170-25-104528.md) | [146](/filings/0001193125-25-267978.md) | [193](/filings/0001193125-26-347842.md) | [189](/filings/0001193125-26-222736.md) | [97.2](/filings/0001193125-26-347842.md) |
| Current assets | $m | [318](/filings/0000950170-23-061484.md) | [315](/filings/0000950170-25-038504.md) | [336](/filings/0000950170-24-056215.md) | [364](/filings/0000950170-24-093268.md) | [381](/filings/0000950170-24-122748.md) | [393](/filings/0001193125-26-115851.md) | [408](/filings/0000950170-25-066342.md) | [450](/filings/0000950170-25-104528.md) | [503](/filings/0001193125-25-267978.md) | [560](/filings/0001193125-26-347842.md) | [575](/filings/0001193125-26-222736.md) | [478](/filings/0001193125-26-347842.md) |
| Total assets | $m | [1,655](/filings/0000950170-23-061484.md) | [1,613](/filings/0000950170-25-038504.md) | [1,643](/filings/0000950170-24-056215.md) | [1,664](/filings/0000950170-24-093268.md) | [1,644](/filings/0000950170-24-122748.md) | [1,663](/filings/0001193125-26-115851.md) | [1,661](/filings/0000950170-25-066342.md) | [1,771](/filings/0000950170-25-104528.md) | [1,810](/filings/0001193125-25-267978.md) | [2,012](/filings/0001193125-26-347842.md) | [2,022](/filings/0001193125-26-222736.md) | [2,106](/filings/0001193125-26-347842.md) |
| Current liabilities | $m | [364](/filings/0000950170-23-061484.md) | [355](/filings/0000950170-25-038504.md) | [382](/filings/0000950170-24-056215.md) | [389](/filings/0000950170-24-093268.md) | [406](/filings/0000950170-24-122748.md) | [402](/filings/0001193125-26-115851.md) | [388](/filings/0000950170-25-066342.md) | [414](/filings/0000950170-25-104528.md) | [410](/filings/0001193125-25-267978.md) | [424](/filings/0001193125-26-347842.md) | [390](/filings/0001193125-26-222736.md) | [411](/filings/0001193125-26-347842.md) |
| Total liabilities | $m | [1,758](/filings/0000950170-23-061484.md) | [1,740](/filings/0000950170-25-038504.md) | [1,777](/filings/0000950170-24-056215.md) | [1,782](/filings/0000950170-24-093268.md) | [1,799](/filings/0000950170-24-122748.md) | [1,785](/filings/0001193125-26-115851.md) | [1,759](/filings/0000950170-25-066342.md) | [1,782](/filings/0000950170-25-104528.md) | [1,801](/filings/0001193125-25-267978.md) | [1,817](/filings/0001193125-26-347842.md) | [1,781](/filings/0001193125-26-222736.md) | [1,818](/filings/0001193125-26-347842.md) |
| Long-term debt | $m | [1,278](/filings/0000950170-23-061484.md) | [1,276](/filings/0000950170-25-038504.md) | [1,275](/filings/0000950170-24-056215.md) | [1,274](/filings/0000950170-24-093268.md) | [1,275](/filings/0000950170-24-122748.md) | [1,272](/filings/0001193125-26-115851.md) | [1,271](/filings/0000950170-25-066342.md) | [1,269](/filings/0000950170-25-104528.md) | [1,289](/filings/0001193125-25-267978.md) | [1,287](/filings/0001193125-26-347842.md) | [1,284](/filings/0001193125-26-222736.md) | [1,285](/filings/0001193125-26-347842.md) |
| Current portion of debt | $m | [9.2](/filings/0000950170-23-061484.md) | [9.2](/filings/0000950170-25-038504.md) | [9.2](/filings/0000950170-24-056215.md) | [9.2](/filings/0000950170-24-093268.md) | [9.2](/filings/0000950170-24-122748.md) | [9.2](/filings/0001193125-26-115851.md) | [9.2](/filings/0000950170-25-066342.md) | [9.2](/filings/0000950170-25-104528.md) | [13.3](/filings/0001193125-25-267978.md) | [13.3](/filings/0001193125-26-347842.md) | [13.3](/filings/0001193125-26-222736.md) | [13.3](/filings/0001193125-26-347842.md) |
| Shareholders' equity | $m | [(106)](/filings/0000950170-24-122748.md) | [(130)](/filings/0001193125-26-115851.md) | [(136)](/filings/0000950170-25-104528.md) | [(119)](/filings/0001193125-25-267978.md) | [(156)](/filings/0001193125-25-267978.md) | [(124)](/filings/0001193125-26-347842.md) | [(100)](/filings/0001193125-26-347842.md) | [(12.0)](/filings/0001193125-26-347842.md) | [9.2](/filings/0001193125-25-267978.md) | [194](/filings/0001193125-26-347842.md) | [240](/filings/0001193125-26-347842.md) | [287](/filings/0001193125-26-347842.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-30) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q4 FY2024 (2024-12-28) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q4 FY2025 (2026-01-03) | Q1 FY2026 (2026-04-04) | Q2 FY2026 (2026-07-04) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [28.7 d](/filings/0000950170-24-122748.md) | [(3.0) d](/filings/0000950170-25-038504.md) | [(12.0)](/filings/0000950170-25-066342.md) | [1.8 d](/filings/0000950170-25-104528.md) | [29.4 d](/filings/0001193125-25-267978.md) | [13.4 d](/filings/0001193125-26-115851.md) | [(8.6)](/filings/0001193125-26-222736.md) | [51.6 d](/filings/0001193125-26-347842.md) | [33.2 d](/filings/0001193125-25-267978.md) | [49.7 d](/filings/0001193125-26-115851.md) | [4.3](/filings/0001193125-26-222736.md) | [80.9 d](/filings/0001193125-26-347842.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-10-01) | Q1 FY2023 (2023-04-01) | Q2 FY2023 (2023-07-01) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q1 FY2026 (2026-04-04) | Q2 FY2026 (2026-07-04) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [186](/filings/0000950170-23-061484.md) | [189](/filings/0000950170-24-056215.md) | [190](/filings/0000950170-24-093268.md) | [189](/filings/0000950170-24-122748.md) | [192](/filings/0000950170-25-066342.md) | [197](/filings/0000950170-25-104528.md) | [193](/filings/0001193125-25-267978.md) | [206](/filings/0001193125-26-222736.md) | [210](/filings/0001193125-26-347842.md) | [222](/filings/0001193125-25-267978.md) | [222](/filings/0001193125-26-222736.md) | [225](/filings/0001193125-26-347842.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 218,219,696 at 2026-08-07, from the cover of the [10-Q filed 2026-08-13](/filings/0001193125-26-347842.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.